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Abstract In recent years, there has been a growing interest,
supported by a large number of experimental and epidemi-
ological studies, for the beneficial effects of some phenolic
substances, contained in commonly used spices and herbs,
in preventing various age-related pathologic conditions,
ranging from cancer to neurodegenerative diseases.
Although the exact mechanisms by which polyphenols
promote these effects remain to be elucidated, several
reports have shown their ability to stimulate a general
xenobiotic response in the target cells, activating multiple
defense genes. Data from our and other laboratories have
previously demonstrated that curcumin, the yellow pigment
of curry, strongly induces heme-oxygenase-1 (HO-1)
expression and activity in different brain cells via the
activation of heterodimers of NF-E2-related factors 2
(Nrf2)/antioxidant responsive element (ARE) pathway.
Many studies clearly demonstrate that activation ofNrf2
target genes, and particularly HO-1, in astrocytes and
neurons is strongly protective against inflammation, oxida-
tive damage, and cell death. In the central nervous system,
the HO system has been reported to be very active, and its
modulation seems to play a crucial role in the pathogenesis
of neurodegenerative disorders. Recent and unpublished
data from our group revealed that low concentrations of
epigallocatechin-3-gallate, the major green tea catechin,
induces HO-1 by ARE/Nrf2 pathway in hippocampal
neurons, and by this induction, it is able to protect neurons
against different models of oxidative damages. Further-
more, we have demonstrated that other phenolics, such as
caffeic acid phenethyl ester and ethyl ferulate, are also able
to protect neurons via HO-1 induction. These studies
identify a novel class of compounds that could be used
for therapeutic purposes as preventive agents against
cognitive decline.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia and the fifth leading cause of death in Americans
aged 65 years and older, but whereas other major causes of
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death have been decreasing, deaths attributable to AD have
been rising dramatically in the last decade (47% increase
between 2000 and 2006) [1]. There is abundant evidence
that both oxidative stress and inflammatory mechanisms
within the CNS contribute to cognitive impairment as AD.
Neurodegeneration in AD appears to be multifactorial,
whereby several biochemical processes operate sequentially
and/or in parallel [2, 3].
Oxidative stress has been implicated in a variety of
pathophysiological conditions, including neurodegenerative,
and is one of the earliest pathological changes in AD. In
particular, cortical and hippocampal oxidative stress is a very
early event in the pathogenesis of sporadic AD and correlates
with the development of specific cognitive deficits in this
condition. Free radicals are produced from a number of
sources, among which are enzymatic, mitochondrial, and
redox metal ion-derived sources [4].
Oxidative damage to key intracellular targets such as
DNA or proteins by free radicals has been shown to be a
major cause of the neuronal cell death related to AD. For
example, recent studies have applied redox proteomic, a
branch of proteomics that identifies oxidatively modified
proteins, to characterize specific proteins in brain aging,
and a number of proteins that are oxidatively modified in
AD have been identified [5]. Aging, the major risk factor
for AD, leads to loss of free radical scavenging ability by
endogenous mechanisms, and it is widely held that free
radical-induced oxidative stress increases in brain aging [6].
Activation of antioxidant pathways is particularly important
for tissues with relatively weak antioxidant defenses, such
as the brain. Increasing evidence points to the notion that
reduced cellular expression and activity of antioxidant
proteins and the consequent oxidative stress are fundamental
causes for brain aging processes and neurodegenerative
diseases [7]. In fact, compared to other organs, the brain is
more susceptible to oxidative stress for the following
reasons: (a) its high content of peroxidizable unsaturated
fatty acids; (b) high oxygen consumption per unit weight; (c)
high content of lipid peroxidation key ingredients (iron and
ascorbate); and (d) the scarcity of antioxidant defense
systems. On the other hand, irrespective of the source and
mechanisms that lead to the generation of intracellular toxic
oxidants, mammalian cells have developed highly refined
inducible systems to counteract stressful conditions [8].
When properly activated, each one of these cell systems
has the possibility to restore cellular homeostasis and
resume the ability to fight off oxidation. Thus, the
malfunctioning of cellular stress response machinery has
been indicated as one of the major causes of inflammatory
and oxidative states of aging.
Since oxidative stress may underlie some aspects of AD
neurodegeneration, and since to date, most of the available
treatments are merely symptomatic [9], considerable research
has been aimed at reducing the effects of oxidative stress in
order to prevent AD progress, by use of free radical
scavengers [10]. Thus, one therapeutic strategy is to delay
the onset of AD dementia sufficiently long as to slow the
neuronal damage associated with Aβ-induced oxidative
stress, particularly Aβ-induced lipid peroxidation. Brain-
accessible antioxidants potentially may provide the means of
implementing this therapeutic strategy of delaying the onset
of AD, acting as neuroprotective agents. By definition,
neuroprotection is an effect that may result in salvage,
recovery, or regeneration of the nervous system, its cells,
structure, and function. Although there are several lines
of evidence supporting the hypothesis that neuroprotec-
tion may be a practical and achievable pharmacological
target, few effective compounds have been developed for
clinical application. To date, the use of antiapoptotic
therapies for neurodegenerative disorders has not been
successful, particularly because many of the compounds
have high levels of toxicity. Moreover, interfering with
apoptotic pathways has often resulted in an augmented
risk of cancerogenesis. On the other hand, the use of safe
antioxidant compounds, such as α-tocopherol, in the
treatment of neurodegenerative disorders is strongly
limited by the difficulty to reach an active concentration
of these molecules in the brain [11]. Thus, in the field of
the pharmacological treatment of neurodegenerative dis-
orders, there remain the need and desire for safe, nontoxic,
and orally effective pharmacological agents able to
interfere with oxidative and inflammatory processes.
Nrf2, HO-1, and Neuroprotection
Although the mechanisms that lead to oxidative stress and
inflammation in the brain are various (still poorly under-
stood), a number of studies suggest an important role for
the transcription factor nuclear factor E2-related factor 2
(Nrf2)-mediated signaling in neuroprotection [12, 13].
Nrf2, a member of the Cap‘n’Collar family of transcription
factors, is sequestered in the cytoplasm by binding to
protein Kelch ECH associating protein 1 (Keap1) in non-
stimulated conditions. Keap1 plays a central role in
regulation of the Nrf2 response. Under normal conditions,
Nrf2 is targeted by Keap1, which promotes Nrf2 proteaso-
mal degradation via interactions with an ubiquitin ligase
[14]. Keap1 further functions as a sensor of stress signals,
through stress-induced oxidation of key cysteine residues
that lead to conformational changes and the inability to
bind Nrf2 [15]. Several stimuli, including oxidative stress
and electrophiles, lead to the disruption of Nrf2/Keap1
complex, freeing Nrf2 for translocation to the nucleus
where it interacts with basic leucine zipper transcription
factors such as Maf and Jun family members and binds
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to a cis-acting element, the antioxidant response element
(ARE, also called EpRE or OSRE). Nrf2-ARE is a major
pathway regulating phase II antioxidant responses,
triggering the simultaneous expression of numerous
protective enzymes and scavengers. Recently, a
genome-scale analysis of the regulatory network gov-
erned by Nrf2 has been performed, using a combination
of high-throughput sequencing for ChIP and microarray-
based gene-expression profiling [16]. The authors have
identified 645 basal and 654 inducible direct target genes
of Nrf2, with 244 genes at the intersection, all involved in
stress response and cell proliferation. The ARE is found in
several cytoprotective inducible genes related to the so-
called cellular stress response, such as the gluthatione-S-
transferases, heme oxygenase 1 (HO-1), glutamate cyste-
ine ligase,ferritin, gamma glutamyl cysteine synthetase,
NAD(P)H quinone oxidoreductase thioredoxin, and peri-
redoxins, and this emphasizes Nrf2 as a central node in
cell survival response.
It has been shown that in neurodegenerative diseases,
Nrf2 expression is altered in both neurons and astrocytes. In
a Parkinson model, Nrf2 deficiency increased sensitivity to
MPTP or 6-hydroxydopamine administration in mice
whereas overexpression of Nrf2 in astrocytes abolished
MPTP or 6-hydroxydopamine toxicity [17]. Furthermore,
Nrf2-knockout mice showed exacerbated gliosis and dopa-
minergic nigrostriatal degeneration [18] and stronger
activation of microglia when treated with MPTP compared
to wild type, highlighting the importance of Nrf2 pathway
in the control of microglial function in Parkinson’s disease
progression [19]. The ability of Nrf2 overexpression to
protect motor neurons, in a transgenic mouse model of
amyotrophic lateral sclerosis (ALS), has been associated to
an increased glutathione secretion from astrocytes [20].
Also, breeding a mouse with Nrf2-overexpressing astro-
cytes with the G93A SOD model of ALS produced delayed
onset of symptoms and improved survival [21]. The
potential role of the Nrf2-ARE pathway in AD genesis
and progression is supported by the fact that Nrf2 levels are
reduced in the hippocampus of AD patients [22]. Moreover,
in transgenic AD mice expressing mutated human amyloid
precursor protein (APP) and presenilin 1 (PS1) genes (APP/
PS1 mice), the Nrf2-ARE pathway is attenuated at the time
of Aβ deposition [23]. Importantly, Nrf2 overexpression in
vitro protects against neurotoxicity of Aβ and is associated
with increased expression of Nrf2 target genes and reduced
oxidative stress [23, 24]. A recent study demonstrated that
direct intrahippocampal gene delivery of Nrf2, by a
lentiviral vector, results in a reduction in spatial learning
deficits in aged APP/PS1 mice [25]. Although it has been
proposed that the beneficial effect of Nrf2 induction in the
central nervous system is based on the actions of astrocytes
[26], this study showed that a beneficial behavioral
outcome in APP/PS1 mice can be achieved by modulating
levels of Nrf2 specifically in neurons.
Among the genes activated by Nrf2/ARE, HO-1 has
been the object of intensive studies in the brain for its
potential role in protecting neurons against cell death. HO-1
is a ubiquitous and redox-sensitive inducible stress protein
and, together with the constitutive isozyme HO-2, provides
the first and rate-limiting step in heme degradation [27].
HO cleaves the heme ring via oxidation at the alpha
methene bridge to give biliverdin, gaseous carbon monoxide,
and free iron. Biliverdin is subsequently converted to bilirubin
by biliverdin reductase, and both these molecules can act as
intracellular antioxidants. A substantial body of evidence
demonstrates that both bilirubin and carbon monoxide (CO)
effectively contribute to modulate important physiological
processes within the cardiovascular, immune, and nervous
systems. These include the regulation of vessel tone,
inhibition of platelet aggregation, and prevention of cell death
and tissue injury. In the CNS, the HO system has been
reported to be very active, and its modulation seems to play a
crucial role in the pathogenesis of neurodegenerative disor-
ders. Deregulation of the HO system has been associated with
the pathogenesis of AD [28], multiple sclerosis, and brain
aging [29, 30].
The HO-1 gene has ARE consensus sequence, responding
to Nrf2, as well as heat shock, AP1, AP2, and NF–κB binding
sites in its promoter region, and it is rapidly upregulated by
oxidative and nitrosative stresses as well as by many toxic
compounds. Many studies clearly demonstrate that activation
of HO-1 in neurons is strongly protective against oxidative
damage and cell death [31, 32]. In fact, the activation of
HO-1 seems to represent an important defensive mechanism
for neurons exposed to oxidative stress.
More recently, HO-1 has also been recognized to exhibit
important immunomodulatory and anti-inflammatory func-
tions. A potential link between HO-1 and inflammation has
initially been shown in an animal model, in which specific
upregulation of HO enzyme activity attenuated complement-
dependent inflammation [33]. Shortly thereafter, it has been
demonstrated in a HO-1 knockout mouse model that these
animals develop a chronic inflammatory disease and are
highly susceptible to an experimental sepsis induced by the
classical pro-inflammatory mediator endotoxin [34]. Impor-
tantly, phenotypical alterations in the only known human
case of genetic HO-1 deficiency are similar to those observed
in HO-1 knockout mice [35]. Independently, targeted over-
expression of HO-1 has been shown to have beneficial
effects in various experimental animal models of inflamma-
tion [36]. Pharmacological induction of HO-1 and exposure
to the end-product of HO-1 activity, CO, prevents the
development of experimental cerebral malaria, by inhibiting
blood–brain barrier (BBB) disruption, brain microvascula-
ture congestion, and neuroinflammation [37]. Induction of
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experimental autoimmune encephalomyelitis (EAE), a model
of multiple sclerosis, in HO-1-knockout mice led to
enhanced CNS demyelination, paralysis, and mortality, as
compared with wild-type mice [38]. In the same study,
induction of HO-1 using cobalt protoporphyrin IX, a specific
HO-1 inducer, modulated ongoing autoimmune neuroin-
flammation, thereby reverting paralysis and leading to
disease remission in mice with previously established EAE.
On the base of such evidences, modulation of Nrf2 and
HO-1 in the brain has been recently suggested as a potential
pharmaceutical strategy for the treatment and prevention of
neurodegenerative disorders and pathologic brain aging.
Synthetic triterpenoids, particularly those which are analogs
of 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic acid
(CDDO), have been shown to induce Nrf2/ARE pathway
in both cell culture and in mice. In an AD transgenic mouse
model, CDDO-methyl amide reduced protein carbonyl
levels, a biomarker of protein oxidation, improved memory,
and reduced amyloid pathology [39]. A recent study has
demonstrated that two CDDO analogs were able to activate
the Nrf2/ARE pathway in the N171-82Q transgenic mouse
model of Huntington’s disease. Nrf2/ARE activation
resulted in the upregulation of different cytoprotective
genes, such as HO-1, decreased oxidative stress, improved
motor performance, and increased survival and rescue of
striatal atrophy in the mice’s brain. Plant-derived pesticide
plumbagin has been recently identified as a novel potent
activator of the Nrf2/ARE pathway, and its administration has
been shown to significantly reduce brain damages and
neurological deficits in a mouse model of focal ischemic
stroke [40]. Several nutritional factors have also been
demonstrated to interfere with Nrf2 signaling in the brain.
A recent study demonstrates for the first time that a relatively
moderate (16 weeks) exposure to a high-fat diet has the
ability to increase brain oxidative stress altering Nrf2
signaling and impair cognitive function in aged animals [41].
Sulforaphane (SFN), a xenobiotic present in cruciferous
vegetables such as broccoli, has been demonstrated to
induce Nrf2-driven genes in rodent brains and microvascu-
lature and by this to reduce brain damages in a traumatic
brain injury model [42]. SFN administration initiated at 1 h
post-cortical impact injury has been shown to improve
cognitive function, in particular spatial learning and
memory, and to reduce working memory dysfunction [43].
In a model of neonatal hypoxia-ischemia, pretreatment
with SFN increased the expression of Nrf2 and HO-1 in the
mouse brain and reduced infarct ratio [44]. Numerous other
non-nutrients contained in food and plants have been
ascribed to the list of Nrf2 activators, and among these
several food-contained antioxidant polyphenols. One of the
most important aspects of current polyphenol research is
the focus on the neuroprotective capacity endowed by these
molecules that seems to be due mostly to their ability to
activate different defensive molecular pathways, instead to
involve just their intrinsic antioxidant properties. In this
regard, our and other laboratories have recently demon-
strated the critical role of Nrf2/HO-1 activation by some of
these neuroprotective compounds, providing insight into
the possible therapeutic significance of a closely related
group of polyphenols against neurodegenerative disorders
and cognitive decline.
Food Polyphenols and Neuroprotection
In recent years, there has been a growing interest, supported
by a large number of experimental and epidemiological
studies, in the beneficial effects of some commonly used
food-derived products in preventing various age-related
pathologic conditions, including brain aging [45]. Spices
and herbs often contain active phenolic substances
endowed with potent antioxidative and chemopreventive
properties [46] and a series of papers focused on specific
neuroprotective effects of some of those polyphenols
derived from nutritional sources [47, 48].
Although clinical studies on cognitive impairment and
specific polyphenol supplementation have yet to be
completed, a number of studies have indicated that
inclusion of antioxidant-rich foods in the diet can improve
cognitive functioning in humans [49]. In elderly non-
demented people, elevated dietary intake of flavonoid-rich
foods was associated with better cognitive function [50].
Additionally, high flavonoid consumption was associated
with attenuation of cognitive decline over a period of
10 years. Other studies have revealed that general dietary
patterns, such as daily fruit and vegetable consumption, and
adherence to a Mediterranean diet emphasizing vegetables
and fruits can decrease the risk of developing dementia in
aging humans [51, 52]. Indeed, a large prospective study of
the relationship between fruit and vegetable consumption
(extending over a period of 10 to 16 years) indicated that
vegetable intake is related to reduced cognitive decline
[53]. This was particularly the case for green leafy
vegetables and cruciferous vegetables. In addition, the
protective effects of dietary polyphenols have also been
reported for non-fruit and vegetable sources; for example, it
has been shown that the intake of wine flavonoids is
inversely related to the incidence of AD [54]. In general,
polyphenols have the capacity to directly quench free
radical species, and this characteristic certainly contributes
to their neuroprotective effects. Beyond the antioxidant
potential, most of these compounds appear to have a
number of different molecular targets, impinging on several
signaling pathways, involving NF–κB, SIRT1, MAPK’s,
heat shock proteins (HSP), and showing pleiotropic activity
on cells and tissues [55]. A possible general mechanism of
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polyphenols healing activity, correlated to their ability to
overexpress highly protective inducible genes, is their
involvement in the cellular stress response [56]. Most
polyphenols show a bell-shaped dose–response curve,
presenting cellular toxicity at high dosage while inducing
light chemical stress at lower concentration with activa-
tion of physiological hormesis in cells [57, 58], resulting
in overexpression of defensive genes (such as those
activated by Nrf2) and improved cellular survival. Our
and other studies have demonstrated that curcumin, the
pigment responsible for curry’s characteristic yellow color,
strongly induce HO-1 and other protein members of Phase
II detoxification through the activation of Nrf2/ARE
pathway in different tissues. Other plant-derived phenolic
agents with analogous chemical structures to curcumin,
such as carnosol [59], zerumbone [60], and rosolic acid
[61], have been demonstrated to strongly activate HO-1
expression and to defend cells against oxidative stress.
Furthermore, in our labs, we have demonstrated that other
phenolics, such as caffeic acid phenethyl ester (CAPE), ethyl
ferulate (EFE), and epigallocatechin-3-gallate (EGCG), are
able to protect neurons via Nrf2/HO-1 induction (Fig. 1).
Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-hepta-
diene-3,5-dione), a coloring agent and food additive
commonly used in Indian culinary and traditional medical
preparations from time immemorial, is extracted from the
rhizome of Curcuma longa [62].
It is a polyphenolic substance that has the potential to
inhibit lipid peroxidation and to effectively intercept and
neutralize ROS (superoxide, peroxyl, hydroxyl radicals)
[63, 64] and NO-based free radicals (nitric oxide and
peroxynitrite) [65]. In this regard, curcumin has been
demonstrated to be several times more potent than vitamin
E [66]. The free radical chemistry of curcumin has focused
on the redox peculiarities of its phenol ring, and the
possible involvement of the β-diketone moiety in the
antioxidant action of curcumin has been considered [67,
68]. In a biological context, a poor correlation between in
vitro and in vivo antioxidant properties of natural com-
pounds has been observed [69]. Beyond its ROS quencher
activity, curcumin effects have been mostly associated to its
ability to interfere at molecular level with numerous cellular
pathways. Of particular interest is the capacity of curcumin
to inhibit COX-1 and COX-2 enzymes [70] and to reduce
the activation of nuclear transcription factor NF–κB [71].
Its anti-inflammatory properties and cancer-preventive
activities have been consistently assessed by using in vitro
and in vivo models of tumor initiation and promotion [72].
In addition to its ability to scavenge carcinogenic free
radicals [73], curcumin also interferes with cell growth
through inhibition of protein kinases. Although the exact
mechanisms by which curcumin promotes these effects
remains to be elucidated, the electrophilic properties of this
yellow pigment appear to be an essential component
underlying its pleiotropic biological activities. Curcumin
contains two electrophilic α,β-unsaturated carbonyl groups,
which can react with nucleophiles such as glutathione [74].
By virtue of its Michael reaction acceptor function and its
electrophilic characteristics, curcumin has been recently
demonstrated to induce Phase II detox system [75, 76],
mostly through the activation of Nrf2/ARE [77]. This
finding is in agreement with other studies demonstrating
that curcumin can increase the activity of γ-glutamyl-
cysteinyl synthetase and other GSH-linked detoxifying
enzymes [78]. Recent and novel data from our group
revealed that low concentrations of curcumin potently
induces HO-1 expression and activity in vascular endothe-
lial cells [79], in rat astrocytes [80], and in cultured
hippocampal neurons [81]. In our experiments, we also
demonstrated that preincubation (12 h) of cultured neurons
with low concentration of curcumin resulted in an enhanced
cellular resistance to glucose oxidase-mediated oxidative
damage; this cytoprotective effect was considerably atten-
uated by zinc protoporphyrin IX, a specific inhibitor of HO




























Fig. 1 The chemical structures of curcumin (a), CAPE (b), EFE (c),
(−)-EGCG (d)
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of curcumin to protect cortical neurons against apoptotic
cell death induced by β-amyloid peptide (1–40) [82]. The
ability of curcumin to induce HO-1 can explain, at least in
part, its strong antioxidant and anti-inflammatory proper-
ties, which depend more on its ability to activate cellular
signals than on its radical scavenger effect [83]. A recent
research demonstrated the ability of curcumin to reduce
brain damages in a rat model of brain focal ischemia, via
the induction of Nrf2/HO-1 [84]. The involvement of
curcumin in restoring cellular homeostasis and rebalancing
redox equilibrium by the activation of defensive genes
suggests that it might be a useful adjunct also in brain aging
and AD treatment [85]. Neuroprotective effects of curcumin
have been demonstrated by Rajakrishnan and colleagues
[86] in ethanol-induced brain damage, in which oral
administration of curcumin to rats caused a significant
reversal in lipid peroxidation, brain lipid modifications, as
well as increase in glutathione levels. Epidemiological
studies suggested that curcumin, as one of the most
prevalent nutritional and medicinal compounds used by
the Indian population, is responsible for the significantly
reduced (4.4-fold) incidence of AD in India compared to
USA [87]. Furthermore, elderly Singaporeans who ate curry
with turmeric had higher MMSE scores than those who did
not [88]. However, the relatively short duration of follow-
up, cultural factors, and other potential confounders suggest
caution in interpreting these findings. Consistent with these
data, Cole and colleagues demonstrated in an Alzheimer
transgenic mouse model (Tg2576) treated for 6 months that
dietary curcumin resulted in a suppression of indices of
inflammation and oxidative brain damage and reversed Aβ-
induced cognitive deficits [89, 90]. Additional researches
from the same group demonstrated that curcumin was a
better Aβ40 aggregation inhibitor than ibuprofen and
naproxen and prevented Aβ42 oligomer formation and
toxicity at very low concentration (between 0.1 and
1.0 μM) [91]. They also showed that curcumin readily
entered the brain in vivo, thus inhibiting the formation of
Aβ oligomers and their toxicity. Among the several
mechanisms by which curcumin is able to clear amyloid
is the induction of HSPs that function as molecular
chaperones to block protein aggregate formation [92].
Curcumin is also highly lipophilic and might cross the
BBB and reach the brain. In fact, although its bioavailabil-
ity is very low, since the drug is rapidly metabolized by
conjugation, curcumin may reach brain concentrations
sufficient to activate signal transduction events and to
decrease Aβ aggregation [93]. Recently, curcumin has been
evaluated in a pilot clinical trial in AD patients, but
preliminary results did not shown measurable beneficial
effects [94]. Caffeic acid phenethyl ester is a phenolic
structurally related to curcumin, originating from plants.
CAPE is, in fact, an active component of propolis derived
from the bark of conifer trees and carried by honeybees
to their hives. The similarity to curcumin is striking
because CAPE is also a Michael reaction acceptor that
has a broad spectrum of biological activities, including
anti-inflammatory [95, 96], antioxidant [97], and anticancer
[98] effects. We have reported that CAPE is a potent
inducer of HO-1 in astroglial cells and in neurons [80,
82]. CAPE is capable of transcriptionally activating a
gene battery that also includes phase II detoxifying
enzymes, through the ARE/Nrf2 pathway, demonstrating
a neuroprotective capacity comparable to curcumin.
Ferulic acid, which is the precursor of lignin biosynthe-
sis, has long been recognized for its antioxidative and
anti-inflammatory activities [99]. Cinnamic acid deriva-
tives, including ferulic acid, are abundant in plants,
playing important roles in the cross-linking of the cell
walls of various lipids. Ferulic acid is found in many fruits
and vegetables such as the tomato [100]. Tomato con-
sumption has been demonstrated to result in absorption
and excretion of ferulic acid by humans [101]. Ferulic acid
has been demonstrated to have antioxidant activity against
peroxynitrite [102] and against lipid peroxidation [103,
104]. It has been demonstrated that ferulic acid was
protective against protein oxidation and lipid peroxidation
in synaptosomal membranes and against cell death and
protein carbonyl formation in neuronal cell culture
induced by the peroxyl radical initiator AAPH [105].
Although it has been shown to be effective in in vitro
experiments, its low lipophilicity impairs its in vivo
efficiency, bioavailability, and stability. Ethyl ferulate,
the naturally occurring ester derivative of ferulic acid, is
present in various systems of many plants, such as the
solanaceae family, as a trace constituent [106, 107]. In
comparison with the corresponding acid form, EFE is
more lipophilic and has been shown to possess better
scavenging properties toward both hydroxyl radicals and
superoxide anions. In a recent study of the inhibitory
effects of antioxidants on lipid oxidation, EFE was shown
to prevent autooxidation of model substrates by extending
the induction time of this process [108].
Data from our lab clearly indicate that EFE is able, at low
concentrations, to induce HO-1 protein expression and
activity in cell lines of rat astrocytes and hippocampal neurons
[109]. In our study, we also demonstrated the cytoprotective
effects of EFE against oxidative damage in neuronal cells.
Accordingly, other studies [110] have shown that EFE exerts
strong neuroprotection against the oxidative stress and
neurotoxicity induced by amyloid β1–42. Green tea, one of
the most widely consumed beverages, has recently attracted
scientific attention as a potential nutritional strategy to
prevent a broad range of age-related chronic disorders,
including cardiovascular diseases [111, 112], cancer [113],
obesity [114], diabetes [115], and neurodegenerative pa-
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thologies [116]. Moreover, a number of epidemiological
studies have suggested that consuming green tea on a daily
basis, as part of a lifestyle, might reduce the onset of age
related diseases and improve longevity [117]. The health-
promoting effects of green tea consumption are mainly
attributed to its polyphenol content, which represents 35%
of the dry weight. Compared with black tea, green tea is
particularly rich in catechins that include: (−)-EGCG, (−)-
epicatechin-3-gallate, (−)-epigallocatechin, and epicatechin.
EGCG is the most active and abundant compound in
green tea, representing approximately 43% of the total
phenols. Many of the aforementioned beneficial effects
of green tea on age-related diseases have been linked to
its EGCG content. EGCG possesses antioxidant and anti-
inflammatory properties, which include the capacity to
inhibit overexpression of cyclooxygenase-2 and nitric
oxide synthase [118]. It also induces apoptosis in several
types of cancer cells by inactivating some transcription
factors, such as NF–κB, AP-1, and STAT-1 [119]. EGCG
prevents cancer cell invasion, angiogenesis, and metasta-
sis by downregulating the expression of matrix metal-
loproteinases and by inhibiting the cell adhesion function
[120]. Several reports have also shown the ability of
EGCG to induce a general xenobiotic response in the
target cells, activating multiple defense genes. In particu-
lar, some studies have recently demonstrated that the
neuroprotective mechanisms of EGCG are partly due to
increasing activities of antioxidant enzymes and decreas-
ing advanced glycation end-product-induced damage in rat
brain or neuronal cells [121]. In a recent study, we
attempted to determine the molecular mechanisms under-
lying the antioxidant effects of EGCG in neurons exposed
to oxidative stress, by focusing on the ability of this
compound to upregulate HO-1 expression and other
adaptive enzymes involved in cellular stress response. In
accordance with other studies [122], we demonstrated the
ability of EGCG to activate HO-1 by the ARE/Nrf2
pathway and by the induction of HO-1 to protect neurons
against oxidative damage [123]. A recent study has
demonstrated the ability of tea epicatechins to protect
neurons and reduce brain infarct size of mice subjected to
middle cerebral artery occlusion or to N-methyl-D-aspar-
tate-induced excitotoxicity. Neuroprotection was mostly
abolished in mice lacking HO1 or the transcriptional factor
Nrf2 and in neurons derived from these knockout mice
[124].
Conclusion
Research described above suggests that polyphenolic com-
pounds exhibit potent antioxidant and anti-inflammatory
activities that may reduce neurodegeneration. The majority
of in vitro and in vivo studies conducted so far have attributed
the protective effect of bioactive polyphenols to their chemical
reactivity toward free radicals and their capacity to prevent the
oxidation of important intracellular components. However,
observations from our and other laboratories reveal a potential
novel aspect in the mode of action of curcumin and curcumin-
like compounds; the ability to activate a physiological
hormetic response in the cells, and the ultimate stimulation
of the Nrf2 pathway, with the expression of phase II and
HO-1 genes, is likely to account for the established and
powerful antioxidant/anti-inflammatory properties of
these plant-derived compounds. Because the HO-1 gene
can be stimulated at transcriptional levels by a plethora
of noxious stimuli, the use of plant-derived natural
substances to trigger HO-1 expression and other intra-
cellular defensive systems via Nrf2 activation, would
clearly offer a greater advantage for therapeutic and
preventive purposes. Recent evidences suggest that that
oxidative stress and inflammation can interfere with the
physiology of learning and memory, and the above-
mentioned pathways might play a relevant role in the
pathogenic mechanism underlying many major cognitive
and behavioral disorders. Many of the polyphenols able
to activate Nrf2 have been shown also to modulate levels
and activity of norepinephrine, serotonin, dopamine, and
glutamate, the principal transmitters involved in addic-
tion. As addiction may be a form of pathological
learning, the role played by food polyphenols may be
hypothesized. It needs to be emphasized that curcumin
and other plant constituents eventually could become part
of the human diet and consumed daily as supplements. A
number of studies identified a novel class of natural
substances that could be used for therapeutic purposes as
potent activators of Nrf2 in the protection of tissues
against inflammatory and neurodegenerative conditions.
Further in vitro and in vivo studies using curcumin-like
molecules will give important information on the feasibility of
developing new pharmacological strategies for maximizing
Nrf2 activity in targeted tissues as an alternative to or in
combination with Nrf2 or HO-1 gene therapy.
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